Objective:To investigate the influence of progesterone on maternal and child outcomes when treating preg nant women with uterine fibroids.Methods:Date of 92 pregnant women with uterine fibroids who came to the Ninth Hospital of Wuhan City of Hubei Province for tocolysis from Jan.2014 to Jan.2017 were retrospective analyzed.The included women were divided into treatment group (46 cases) and control group (46 cases) according to whether to used progesterone for tocolytic therapy.The progesterone levels,fibroids size before and after treated,incidence of red degeneration,rate of obstetric complications,and progesterone receptor expression of women in the two groups were compared.Results:There was no significant difference in progesterone level of women at first trimester between the two groups (P＞0.05),but progesterone level of women in treatment group at cesarean section time was significant higher than that of women in control group (P＜0.05).At cesarean section time,the sizes of fibroids of women in both groups was significant bigger than those of women at first trimester (P＜0.05),but there was no significant difference in sizes of fibroids of women at first trimester between the two groups (P＞0.05).The incidence of uterine fibroids red degeneration of women in treatment group was 60.9 ％,which had no statistical significant difference when compared to that of women(56.5 ％) in control group (P ＞ 0.05).The total incidence of obstetric complications,Intraoperative blood loss,operative time,neonate apgar score and time of hospital stay of women between the two groups had no significant difference (P＞0.05).The positive rate of progesterone receptor of women in treatment group was 87.0％,which had no statistical significant difference when compared to that of women(80.7％) in control group (P＞0.05).Conclusion:When progesterone treating pregnant women with uterine fibroids for tocolysis,it has no side effect on uterine fibroids and complications of maternal and child,and it doesn't increase the incidence of red degeneration of uterine fibroids.%目的:探究孕激素辅助治疗妊娠合并子宫肌瘤对母婴结局的影响.方法:回顾性分析2014年1月一2017年1月本院保胎治疗的妊娠合并子宫肌瘤患者资料92例,根据临床是否给予孕激素治疗分为治疗组和对照组各46例.比较两组孕酮水平、肌瘤变化情况、红色变性发生率、产科并发症发生率及子宫肌瘤孕激素受体的表达情况.结果:孕早期两组孕酮水平无差异(P＞0.05),剖宫产时治疗组高于对照组(P＜0.05).剖宫产时两组子宫肌瘤大小均较孕早期增大(P＜0.05),但同期大小比较组间无差异(P＞0.05);治疗组子宫肌瘤红色变性发生率(60.9％)与对照组(56.5％)无差异(P＞0.05);两组产科并发症总发生率、术中失血量、手术时间、胎儿Apgar评分、住院时间等比较无差异(P＞0.05);子宫肌瘤孕激素受体阳性率治疗组(87.0％)与对照组(80.7％)无差异(P＞0.05).结论:对妊娠合并子宫肌瘤孕妇进行保胎治疗时应用孕激素,未见对子宫肌瘤、胎儿及产科并发症有明显影响,且肌瘤红色变性发生率也未出现增高.
展开▼
